BIIB
Price
$135.33
Change
+$2.31 (+1.74%)
Updated
Jul 10 closing price
Capitalization
31.34B
20 days until earnings call
LLY
Price
$790.65
Change
+$3.73 (+0.47%)
Updated
Jul 10 closing price
Capitalization
739.66B
27 days until earnings call
Interact to see
Advertisement

BIIB vs LLY

Header iconBIIB vs LLY Comparison
Open Charts BIIB vs LLYBanner chart's image
Biogen
Price$135.33
Change+$2.31 (+1.74%)
Volume$992.05K
Capitalization31.34B
Eli Lilly & Co
Price$790.65
Change+$3.73 (+0.47%)
Volume$3.13M
Capitalization739.66B
BIIB vs LLY Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. LLY commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and LLY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (BIIB: $135.33 vs. LLY: $790.65)
Brand notoriety: BIIB and LLY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 66% vs. LLY: 84%
Market capitalization -- BIIB: $31.34B vs. LLY: $739.66B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. LLY’s [@Pharmaceuticals: Major] market capitalization is $739.66B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • LLY’s FA Score: 2 green, 3 red.
According to our system of comparison, LLY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 5 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 2 bearish.
  • LLY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than LLY.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +1.85% price change this week, while LLY (@Pharmaceuticals: Major) price change was +1.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.39%. For the same industry, the average monthly price growth was +1.04%, and the average quarterly price growth was +11.01%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

LLY is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.39% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LLY($740B) has a higher market cap than BIIB($31.3B). LLY has higher P/E ratio than BIIB: LLY (131.13) vs BIIB (26.95). LLY YTD gains are higher at: 2.803 vs. BIIB (-11.503). LLY has higher annual earnings (EBITDA): 8.57B vs. BIIB (2.04B). LLY has more cash in the bank: 2.93B vs. BIIB (1.05B). BIIB has less debt than LLY: BIIB (7.34B) vs LLY (25.2B). LLY has higher revenues than BIIB: LLY (34.1B) vs BIIB (9.84B).
BIIBLLYBIIB / LLY
Capitalization31.3B740B4%
EBITDA2.04B8.57B24%
Gain YTD-11.5032.803-410%
P/E Ratio26.95131.1321%
Revenue9.84B34.1B29%
Total Cash1.05B2.93B36%
Total Debt7.34B25.2B29%
FUNDAMENTALS RATINGS
BIIB vs LLY: Fundamental Ratings
BIIB
LLY
OUTLOOK RATING
1..100
6419
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
10011
SMR RATING
1..100
7115
PRICE GROWTH RATING
1..100
6157
P/E GROWTH RATING
1..100
9796
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LLY's Valuation (83) in the Pharmaceuticals Major industry is in the same range as BIIB (88) in the Biotechnology industry. This means that LLY’s stock grew similarly to BIIB’s over the last 12 months.

LLY's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that LLY’s stock grew significantly faster than BIIB’s over the last 12 months.

LLY's SMR Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (71) in the Biotechnology industry. This means that LLY’s stock grew somewhat faster than BIIB’s over the last 12 months.

LLY's Price Growth Rating (57) in the Pharmaceuticals Major industry is in the same range as BIIB (61) in the Biotechnology industry. This means that LLY’s stock grew similarly to BIIB’s over the last 12 months.

LLY's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as BIIB (97) in the Biotechnology industry. This means that LLY’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBLLY
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
46%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
69%
Momentum
ODDS (%)
Bullish Trend 1 day ago
54%
Bearish Trend 1 day ago
57%
MACD
ODDS (%)
Bullish Trend 1 day ago
53%
Bearish Trend 1 day ago
58%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
54%
Bullish Trend 1 day ago
68%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
69%
Advances
ODDS (%)
Bullish Trend 9 days ago
54%
Bullish Trend 1 day ago
69%
Declines
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 21 days ago
52%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
54%
Bearish Trend 1 day ago
52%
Aroon
ODDS (%)
Bullish Trend 1 day ago
30%
Bullish Trend 1 day ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BGDV25.460.18
+0.72%
Bahl & Gaynor Dividend ETF
IHDG45.750.18
+0.39%
WisdomTree Intl Hdgd Qual Div Gr ETF
FORH23.490.01
+0.04%
Formidable ETF
SOVF30.600.01
+0.04%
Sovereign's Capital Flourish Fund
NUMG48.40-0.29
-0.60%
Nuveen ESG Mid-Cap Growth ETF

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+1.74%
AMGN - BIIB
56%
Loosely correlated
+1.30%
PFE - BIIB
50%
Loosely correlated
+0.86%
SNY - BIIB
46%
Loosely correlated
+1.04%
NVS - BIIB
45%
Loosely correlated
+0.64%
MRK - BIIB
44%
Loosely correlated
+0.37%
More